← All trials
NCT05255653
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 11, 2021
- Primary completion
- Jan 1, 2030
- Completion date
- Jan 1, 2031
- First posted
- Feb 24, 2022
- Last posted
- Oct 19, 2022
- Enrollment
- 1611
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Leiden UniversityLead sponsor
- AstraZenecaCollaborator
- Barts & The London NHS TrustOverall official - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Cancer Research UKCollaborator
- Netherlands Cancer InstituteCollaborator
- Dutch Cancer SocietyCollaborator
- Leiden UniversityReponsible party - principal investigator
- National Cancer Institute, FranceCollaborator
- University of TorontoOverall official - principal investigator
- University of British ColumbiaOverall official - principal investigator
- Leiden UniversitySponsor investigator
- Barts & The London NHS TrustOfficial
- University of British ColumbiaOfficial
- Leiden UniversityOfficial
- Leiden UniversityCollaborator
- University of TorontoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.